PRODUCT DETAILS VIEW ALL PRODUCTS

Diapride M2 HV Tablets (Glimepiride + Metformin +Voglibose )

  • Each tablet contains Glimepiride 2 mg + Metformin 500 mg SR + Voglibose 0.3mg.
  • Indicated in patients with Type-2 Diabetes Mellitus inadequately controlled with dual therapy.
  • The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. In addition, extra-pancreatic effects may also play a role in the activity of sulphonylureas such as glimepiride. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.Voglibose is an alpha-glucosidase inhibitor which reduces intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of alpha-glucosidase in the intestinal brush border.
  • Twice daily before meals.
  • Contraindicated in patients with known hypersensitivity to the drug.Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
  • Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake, while receiving metformin. Voglibose should be administered with caution to the following patients: patients with history of laparotomy or ileus; patients with chronic intestinal disease accompanied by disturbance in digestion and absorption; patients with aggravating symptoms due to increased generation of intestinal gas.Glimepiride is capable of producing severe hypoglycaemia.Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anaemia.
  • Should not be used in pregnancy and lactation. Safety and effectiveness is not established in paediatric population.
  • Miconazole and Phenylbutazone: Increases hypoglycemic effect of glimepiride.If salicylates are administered or discontinued in patients receiving oral antidiabetic agents, patients should be monitored for hypoglycemia or loss of blood glucose control. When voglibose is used in combination with derivative(s) of sulfonylamide, sulfonylurea or biguanide, or with insulin, hypoglycemic symptoms may occur.Levothyroxine can reduce the hypoglycemic effect of metformin.Metformin may result in suboptimal oral vitamin B12 absorption by competitively blocking the calcium dependent binding of the intrinsic factor vitamin B12 complex to its receptor.
  • When voglibose is used in combination with other antidiabetic drugs, hypoglycemia may occur.Glimepiride appears to be associated with a low incidence of hypoglycemia. Nausea, diarrhoea, abdominal pain, constipation, vomiting, metallic taste in mouth have been reported with metformin therapy.
  • Anti-Diabetic agents